虹膜荧光血管造影联合眼底荧光血管造影在全视网膜激光光凝术后糖尿病视网膜病变患者中的应用研究

目的　探讨虹膜荧光血管造影（ｉｒｉｓｆｌｕｏｒｅｓｃｅｉｎａｎｇｉｏｇｒａｐｈｙ，ＩＦＡ）联合眼底荧光血管造影（ｆｕｎｄｕｓｆｌｕｏｒｅｓｃｅｉｎａｎｇｉｏｇｒａｐｈｙ，ＦＦＡ）检查在全视网膜激光光凝术后（ｐａｎｒｅｔｉｎａｌｐｈｏ-ｔｏｃｏａｇｕｌａｔｉｏｎ，ＰＲＰ）增生型糖尿病视网膜病变患者中的临床应用。方法　对ＰＲＰ术后的６５例１２３眼增生型糖尿病视网膜病变患者均行视力、眼压、裂隙灯、ＩＦＡ联合ＦＦＡ检查。采用非参数检验法对比分析裂隙灯和ＩＦＡ检测虹膜新生血管灵敏性的差异。结果　ＦＦＡ显示１２３眼中，２１眼视网膜无灌注区，３９眼视网膜新生血管，１２眼玻璃体积血和３２眼黄斑水肿。ＩＦＡ显示１２３眼中，９７眼无糖尿病虹膜病变，１３眼非增生型虹膜病变，１１眼增生型虹膜病变，２眼新生血管性青光眼。所有非增生型虹膜病变眼不能被裂隙灯发现，能被ＩＦＡ检测。ＩＦＡ检查发现虹膜新生血管眼（１１眼）比裂隙灯检查（５眼）更灵敏（Ｐ＝０．０３）。结论　ＩＦＡ联合ＦＦＡ检查能及早发现ＰＲＰ术后的增生型糖尿病视网膜病变合并糖尿病虹膜病变患者，为及时治疗提供帮助。

Application of iris fluorescein angiography combined with fundus fluorescein angiography in proliferative diabetic retinopathy patients after panretinal photocoagulation

Objective To evaluate the effects of iris fluorescein angiography (IFA) combined with fundus fluorescein angiography ( FFA) in proliferative diabetic retinopathy ( PDR) patients after panretinal photocoagulation ( PRP) . Methods One hundred and twenty-three eyes of 65 PDR patients after PRP underwent an ophthalmic exanunations that included best-corrected visual acuity , intraocular pressure , slit lamp , IFA and FFA. The sensitivity of slit lamp and IFA in the eyes with iris neovascularization was comparatively analyzed. Statistical analyses was performed by Nonparametric Test. Results Of the 123 eyes,21 eyes with no perfusion area,39 eyes with retinal neovascularization , 12 eyes with vitreous hemorrhage and 32 eyes with macular edema were diagnosed by FFA. Of all the eyes ,97 eyes of no diabetic iridopathy , 13 eyes of non-proliferative diabetic iridopathy, 11 eyes of proliferative diabetic iridopathy and 2 eyes of neovascular glaucoma were detected by IFA. The detection of all non-proliferative diabetic iridopathy eyes was not slit lamp , but IFA. IFA group ( II eyes) was more sensitive in proliferative diabetic iridopathy detection than slit lamp group ( 5 eyes) ( P = 0. 03 ) . Conclusion IFA combined with FFA can bring an early detection and provide the help of rapid treatments in PDR patients with diabetic iridopathy after PRP.